Evidence map›Paper›PMID 33201252›Full record

ReviewCellular and molecular life sciences : CMLS2021

BCL2L13: physiological and pathological meanings.

Fei Meng, Naitong Sun, Dongyan Liu, Jia Jia, Jun Xiao, Haiming Dai

Open access · greenAbstract readReview
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 72 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Forward genetic screening in engineered colorectal cancer organoids identifies regulators of metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Fei Meng *Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health & Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.ORCID http://orcid.org/0000-0001-9623-6883
Naitong Sun *Department of Hematology, the Third People's Hospital of Yancheng, Yancheng, 224001, China.
Dongyan LiuAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health & Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Jia JiaAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health & Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Jun XiaoDepartment of Urology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China. xiaojunpp@126.com.
Haiming DaiAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health & Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China. daih@cmpt.ac.cn.
University of Science and Technology of China · CNChinese Academy of Sciences · CNYancheng Third People's Hospital · CN

Funding

co-operative grant from Anhui Medical University and Center of Medical Physics and Technology No. LHJJ202006co-operative grant from Anhui Medical University and Center of Medical Physics and Technology No. LHJJ202007National Natural Science Foundation of China No. 21772201National Natural Science Foundation of China No. 31970701National Natural Science Foundation of China No. 82072807
6 · The paper itself

Abstract

BCL2L13 is a BCL2-like protein. It has been discovered for two decades, now on the way to be a hotspot of research with its physiological and pathological meanings found in recent years. Start with the pro-apoptotic activity, there have been reported consecutively that BCL2L13 could also induce mitochondrial fragmentation, inhibit cell death and promote mitophagy. Similar to BNIP3, BCL2L13 cannot be indiscriminately categorized into pro- or anti-apoptotic proteins. It anchors in the mitochondrial outer membrane, and expresses in various cells and tissues. This article reviews for the first time that BCL2L13 functions in physiological processes, such as growth and development and energy metabolism, and its dysregulation participating in pathological processes, including cancer, bacterial infection, cardiovascular diseases and degenerative diseases, suggesting its important roles in these events.

Indexed as

AnimalsApoptosisEnergy MetabolismHumansMicroRNAsMitochondriaMitophagyNeoplasmsNeurodegenerative DiseasesProto-Oncogene Proteins c-bcl-2BCL2L13 protein, humanMicroRNAsProto-Oncogene Proteins c-bcl-2ApoptosisAutophagyBCL-ramboCerebrovascular accidentNeurodegenerative disordersTumor

Identifiers

PMID33201252
PMCPMC11073179
OpenAlexW3101289582

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.